NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
12.16
+0.31 (2.62%)
Mar 31, 2025, 2:25 PM EDT - Market open
NeuroPace Revenue
In the year 2024, NeuroPace had annual revenue of $79.91M with 22.14% growth. NeuroPace had revenue of $21.47M in the quarter ending December 31, 2024, with 19.18% growth.
Revenue (ttm)
$79.91M
Revenue Growth
+22.14%
P/S Ratio
4.32
Revenue / Employee
$434,272
Employees
184
Market Cap
395.93M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NPCE News
- 5 days ago - NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 26 days ago - NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 27 days ago - UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 27 days ago - NeuroPace to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. - GlobeNewsWire
- 5 weeks ago - NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - GlobeNewsWire
- 5 weeks ago - NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire